普丽妍获近5000万美元C轮融资，未来资产资本领投

Core Insights - Puliyan Medical Technology Co., Ltd. has completed a nearly $50 million Series C financing round, led by Future Asset Capital (China) with participation from existing shareholders Yahui Investment and Huatai Zijin [1][2] - The company focuses on medical polymer materials and biological tissue engineering, aiming to provide safer and more effective beauty solutions [1][3] - The financing will primarily be used for the development of multiple injection-based aesthetic products, market promotion, channel construction, and expansion [1] Company Overview - Founded in May 2018, Puliyan is a high-tech enterprise dedicated to the medical aesthetics industry, emphasizing serious medical standards in product development [1] - The company has established key technology platforms for the engineering preparation of polymer microspheres and animal-derived decellularized matrix particles [1][3] - Puliyan's product matrix includes a series of regenerative aesthetic products, with Tongyan injection being a representative product [1] Market Potential - The Chinese medical aesthetics market is transitioning from "filling and modification" to "regenerative medicine," presenting significant growth opportunities [2][3] - The regenerative aesthetic market is expected to experience explosive growth, potentially exceeding 100 billion in the next decade [3] - Companies with capabilities in regenerative material research, medical device development, and brand building are likely to lead the industry into a new phase of "endogenous activation" [3]